All In Biotech

Drug Trial Radar · NCT00708162

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults

Last checked: Nov 20, 2026Latest source record: May 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 724 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

724

Actual

Start

Jul 2008

Primary completion

Dec 2010

Study completion Apr 2015

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 2, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety, tolerability and efficacy of a regimen containing once-daily elvitegravir (EVG) versus twice-daily raltegravir (RAL) added to a background regimen (1 fully-active ritonavir (RTV)-boosted protease inhibitor (PI) plus 1 or 2 additional antiretroviral (ARV) agents) in HIV-1 infected, ARV treatment-experienced adults who have documented resistance, or at least six months experience prior to screening with two or more different classes of ARV agents. Participants will be randomized in a 1:1 ratio to receive EVG plus background regimen (Elvitegravir group), or raltegravir plus background regimen (Raltegravir group). Due to known drug interactions, participants in the Elvitegravir group receiving RTV-boosted atazanavir (ATV) or RTV-boosted lopinavir (LPV) as part of their background regimen will receive elvitegravir at a lower dose (85 mg).

Conditions

  • HIV Infection

Interventions

  • ElvitegravirDrug

    Elvitegravir (EVG) tablet administered orally once daily with food

  • RaltegravirDrug

    Raltegravir tablet administered orally twice daily according to prescribing information

  • EVG placeboDrug

    Placebo to match elvitegravir administered orally once daily

  • RAL placeboDrug

    RAL placebo administered orally twice daily.

  • Background regimenDrug

    Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48

Locations

180 sites in 14 countries. Site status is shown where the registry gives one.

  • Southwest Center for HIV/AIDS

    Phoenix, Arizona

  • Health for Life Clinic, PLLC

    Little Rock, Arkansas

  • Pacific Oaks Medical Group

    Beverly Hills, California

  • AIDS Healthcare Foundation-Research Center

    Beverly Hills, California

  • Center for Special Immunology

    Fountain Valley, California

  • The Living Hope Foundation

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Jeffrey Goodman Special Care Clinic

    Los Angeles, California

  • University of Southern California, AIDS Clinical Trials Unit

    Los Angeles, California

  • Peter J. Ruane, MD, Inc.

    Los Angeles, California

  • Tony Mills, MD Internal Medicine

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • Alameda County Medical Center

    Oakland, California

  • East Bay AIDS Center

    Oakland, California

  • Kaiser Permanente

    Sacramento, California

  • David J. Shamblaw, MD Inc.

    San Diego, California

  • Metropolis Medical

    San Francisco, California

  • San Francisco VA Medical Center/UCSF

    San Francisco, California

  • Connecticut Health Care Group

    Glastonbury, Connecticut

  • Circle Medical LLC

    Norwalk, Connecticut

  • The Stamford Hospital - Stamford ID

    Stamford, Connecticut

  • Whitman-Walker Clinic

    Washington D.C., District of Columbia

  • The George Washington University Medical Center

    Washington D.C., District of Columbia

  • South Florida Clinical Research

    Atlantis, Florida

  • Lifeway , Inc.

    Fort Lauderdale, Florida

  • NorthPoint Medical

    Fort Lauderdale, Florida

  • Therafirst Medical Centers

    Fort Lauderdale, Florida

  • Broward Health CCC

    Fort Lauderdale, Florida

  • Gary Richmond, MD, PA, Inc.

    Fort Lauderdale, Florida

  • Associates In Infectious Diseases

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    North Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Infectious Disease of Central Florida

    Orlando, Florida

  • Barry M. Rodwick, M. D.

    Safety Harbor, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • Treasure Coast Infectious Disease Consultants

    Vero Beach, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • The Emory Clinic, Inc., Division of Infectious Diseases

    Atlanta, Georgia

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.